Abstract
Purpose :
To evaluate improvement in best-corrected visual acuity (BCVA), contrast sensitivity (CS), ocular aberrations (OA in patients with irregular cornea and a successful adaptation of scleral contact lenses (SCL)
Methods :
Prospective, longitudinal and comparative study in patients using SCL between 2022 and 2023. Patients of both sexes, older than 18 years old were included. Institutional ethics committee approved the study, participants signed informed consent. The tests were performed with and without SCL: BCVA (ETDRS), CS (FACT), anterior cornea aberration and SCL (ATLAS, Carl Zeiss, Germany), and OA (WASCA, Carl Zeiss, Germany) under mydriasis
Results :
38 eyes were included. 15 (76.3%) males. Mean (SD) age: 27.5±8.6. Most frequent indication was keratoconus (78.3%). SCL more frequently used was One fit® (68.4%). Median (IQR) BCVA (Log Mar) improved with SCL (60.5(51.5-78.3) vs 77.5 (71.8-84), p<0.001). CS improved with SCL, A (18 vs 36), B (20 vs 40), C (12 vs 33), D (0 vs 11) p<001. Median (IQR) OA and HOA (RMS) improved with SCL: 4.1(2.9-7.93) vs 2.1(0.9-2.53), p=0.001), HOA: 0.96 (0.8-1.4) vs 0.6(0.5-0.74), p=0.001.
Conclusions :
This study on irregular corneas demonstrates that SCL provides a significant improvement in BCVA, CS, OA and HOA.
This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.